Molecular Biology
Global

Molecular Biology Experts

Mark R. Gilbert

Chief
Center for Cancer Research
National Cancer Institute
United States of America

Mark R. Gilbert

Biography

Dr. Gilbert received his medical doctorate (M.D.) degree in medicine from Johns Hopkins University (JHU) in 1982 (Alpha Omega Alpha). At JHU, he completed residencies in internal medicine (1982-1985) and neurology (1984-1988) and fellowship training (Keck Foundation Fellowship) in both neurology and neuro-oncology. In 2000, after serving on the faculties of the University of Pittsburgh and Emory University in Atlanta, Georgia, Dr. Gilbert joined the University of Texas MD Anderson Cancer Center as Deputy Chair of the Department of Neuro-oncology. In 2005, he was appointed as Director of the Brain Tumor Trials Collaborative, a multi-center clinical trials consortium. In 2009, Dr. Gilbert received the Blanche Bender Endowed Professorship in Cancer Research. Recently, he was named the Co-Chair of the Brain Tumor Committee in the Radiation Therapy Oncology Group (RTOG). Dr. Gilbert is also the founder and former leader of the Collaborative Ependymoma Research Network (CERN), a consortium studying ependymoma, a rare central nervous system cancer, by supporting basic research, clinical trials, patient outcomes research and educational efforts in North America and Europe.

Research Interest

neuro-oncology, neurology, primary brain tumors, development of new treatment strategies

Publications

  • Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, DeAngelis LM, Chang S, Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of neuro-oncology. 2012 Jan 1;106(1):147-53.

  • Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro-oncology. 2010 Aug 20;12(11):1167-72.

  • Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine. 2014 Feb 20;370(8):699-708.

Global Experts from United States of America

Global Experts in Subject